Micrometastasis in Gastrointestinal Cancer

• Conditions: Colorectal Cancer; Pancreatic Adenocarcinoma

• Registration Number: NCT01919151
• Lead Sponsor: Oslo University Hospital

Brief Summary

Prognostic and predictive value of assessing the patients micrometastasis status in blood and bone marrow when diagnosed GI cancer. 2 different patient subgroups are currently studied, patients with cancer of the pancreas and patients with liver metastasis secondary to colorectal cancer.

Our hypothesis is that patients with detective circulating tumor cells in the blood or disseminated tumour cells in their bone marrow at diagnosis have a more advanced disease than negative patients. This information may be of therapeutic interest.

Detailed Description

Oncological and overall outcome of the included patients are consecutively registrated at the out-patient clinic. At end of follow-up these survival data are analysed according to the presence of tumor cells in blood and bone marrow, and the prognostic impact of their presence are assessed.

Study Timeline

• Study Start: 2008-06
• Status Verified: 2013-08
• Study First Submitted: 2013-08-07
• Study First Submitted QC: 2013-08-07
• Study First Posted: 2013-08-08
• Last Update Submitted: 2013-08-08
• Last Update Posted: 2013-08-12
• Primary Completion: 2013-12
• Study Completion: 2015-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

1. Histological proven adenocarcinoma of the pancreas
2. Histological/radiological verified colorectal liver metastases
3. Consent capable patient
4. Signed written, informed consent

Exclusion Criteria

1. Patient'history of other malignancy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Survival	5 year

Trial Locations

Locations (1)

Oslo University Hospital; 🇳🇴 Oslo, Norway